Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP
First Claim
Patent Images
1. A synthetic, oligonucleotide of 15-25 nucleotides in length having at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to and specifically hybridizes to a complementary 15-25 nucleotide region of a natural antisense polynucleotide of a ‘
C terminus of HSP70-Interacting Protein (CHIP) polynucleotide having SEQ ID NOS;
2 or 3 and upregulates the function and/or expression of a ‘
C terminus of HSP70-Interacting Protein’
(CHIP) gene in vivo or in vitro as compared to a normal control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.
-
Citations
15 Claims
-
1. A synthetic, oligonucleotide of 15-25 nucleotides in length having at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to and specifically hybridizes to a complementary 15-25 nucleotide region of a natural antisense polynucleotide of a ‘
C terminus of HSP70-Interacting Protein (CHIP) polynucleotide having SEQ ID NOS;
2 or 3 and upregulates the function and/or expression of a ‘
C terminus of HSP70-Interacting Protein’
(CHIP) gene in vivo or in vitro as compared to a normal control. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- at least one modified sugar moiety;
-
15. A composition comprising an oligonucleotide and a pharmaceutically acceptable excipient wherein the oligonucleotides have at least about 95% sequence identity as compared to any one of the nucleotide sequences set forth as SEQ ID NOS:
- 4, 5, 6, 7 and 9.
Specification